---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Safety questions"
description: "Safety questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: Do patients develop antibodies to Nucala in severe asthma? What are the most common side effects of Nucala for severe asthma? How many patients stopped Nucala due to side effects in severe asthma trials? Can Nucala cause shingles (herpes zoster)? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Safety questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Safety questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications: Safety](https://www.evicenter.com/medical-information/nucala/safety).

## Safety

<a id="nucala-antibodies"></a>

### Do patients develop antibodies to Nucala in severe asthma?

> “In adult and adolescent patients with severe asthma receiving NUCALA 100 mg, 15/260 (6%) 
> had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient 
> with asthma receiving NUCALA 100 mg. Anti-mepolizumab antibodies slightly increased 
> (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation 
> between anti-mepolizumab antibody titers and change in eosinophil level. The clinical relevance 
> of the presence of anti-mepolizumab antibodies is not known. In the clinical trial of children 
> aged 6 to 11 years with severe asthma receiving NUCALA 40 or 100 mg, 2/35 (6%) had 
> detectable anti-mepolizumab antibodies during the initial short phase of the trial. No children had 
> detectable anti-mepolizumab antibodies during the long phase of the trial.”

Source: [NUCALA: Prescribing information, page 19, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=19)

## Side effects

<a id="nucala-common-side-effects"></a>

### What are the most common side effects of Nucala for severe asthma?

> “Most common adverse reactions (≥5%):
>
> Severe asthma trials: headache, injection site reaction, back pain, fatigue”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=Most%20common%20adverse%20reactions%20%28%E2%89%A55%25%29%3A,site%20reaction%2C%20back%20pain%2C%20fatigue)

> “The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory 
> efficacy and safety trials MENSA and SIRIUS with NUCALA 100 mg is shown in Table 2.”

Source: [NUCALA: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=7)

> “Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common 
> than Placebo in Patients with Severe Asthma (MENSA and SIRIUS) 
> Adverse Reaction 
> NUCALA 
> (Mepolizumab 100 mg 
> Subcutaneous) 
> (n = 263) 
> % 
> Placebo 
> (n = 257) 
> % 
> Headache 
> 19 
> 18 
> Injection site reaction 
> 8 
> 3 
> Back pain 
> 5 
> 4 
> Fatigue 
> 5 
> 4 
> Influenza 
> 3 
> 2 
> Urinary tract infection 
> 3 
> 2 
> Abdominal pain upper 
> 3 
> 2 
> Pruritus 
> 3 
> 2 
> Eczema 
> 3 
> <1 
> Muscle spasms 
> 3 
> <1”

Source: [NUCALA: Prescribing information, page 8, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=8)

Note: Table 2 lists each adverse reaction with the NUCALA percentage (n = 263) followed by the placebo percentage (n = 257).

<a id="nucala-stopping-for-side-effects"></a>

### How many patients stopped Nucala due to side effects in severe asthma trials?

> “A total of 1327 patients ≥12 years of age with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks’ duration: Trial 1,* Trial 2, and Trial 3. Approximately 2% of patients receiving NUCALA withdrew from these clinical trials due to adverse events vs 3% of patients receiving placebo.”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=A%20total%20of%201327%20patients,3%25%20of%20patients%20receiving%20placebo.)

> “*Trial 1: 52-week dose-ranging exacerbation study.”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=%2ATrial%201%3A%2052%2Dweek%20dose%2Dranging%20exacerbation%20study.)

<a id="nucala-injection-site-reactions"></a>

### How common are Nucala injection site reactions in severe asthma?

> “Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling, itching, burning 
> sensation) occurred at a rate of 8% in patients receiving NUCALA 100 mg compared with 3% in 
> patients receiving placebo.”

Source: [NUCALA: Prescribing information, page 9, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=9)

<a id="nucala-side-effects-children"></a>

### What side effects do children 6 to 11 have on Nucala?

> “Adverse Reactions in Pediatric Patients Aged 6 to 11 Years with Severe Asthma 
> The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients 
> with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 
> 100 mg (for those weighing ≥40 kg) of NUCALA administered subcutaneously once every 
> 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment 
> interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The 
> adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients 
> aged 12 years and older.”

Source: [NUCALA: Prescribing information, page 9, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=9)

Note: The approved dose for ages 6 to 11 is 40 mg every 4 weeks; the 100 mg dose in this trial was given to children weighing 40 kg or more.

## Warnings

<a id="nucala-herpes-zoster"></a>

### Can Nucala cause shingles (herpes zoster)?

> “Opportunistic Infections: Herpes Zoster
>
> Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.”

Source: [NUCALA: SEA Safety Profile, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/safety-profile/#:~:text=Opportunistic%20Infections%3A%20Herpes%20Zoster,Consider%20vaccination%20if%20medically%20appropriate.)

> “Serious adverse events that occurred in more than 1 patient and in a greater 
> percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included 1 
> event, herpes zoster (2 patients vs. 0 patients, respectively).”

Source: [NUCALA: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=7)

Note: The second passage is from the label's description of the severe asthma trials and compares patients who received NUCALA 100 mg subcutaneously (n = 263) with placebo (n = 257).

<a id="nucala-allergic-reactions"></a>

### Can Nucala cause allergic reactions or anaphylaxis?

> “Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, 
> rash) have occurred following administration of NUCALA. These reactions generally occur 
> within hours of administration, but in some instances can have a delayed onset (i.e., days). In the 
> event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications 
> (4)].”

Source: [NUCALA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=6)

> “Systemic Reactions, including Hypersensitivity Reactions: In the Severe Asthma Trials DREAM, 
> MENSA, and SIRIUS described above, the percentage of patients who experienced systemic 
> (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in 
> the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients 
> in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most 
> commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the 
> group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic 
> non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg 
> and 3% of patients in the placebo group. The most commonly reported manifestations of 
> systemic non-allergic reactions reported in the group receiving NUCALA 100 mg included rash, 
> flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 
> 100 mg (5/7) were experienced on the day of dosing.”

Source: [NUCALA: Prescribing information, page 8, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=8)

> “Hypersensitivity reactions, including anaphylaxis.”

Source: [NUCALA: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=12)

Note: The third passage is the label's postmarketing report under Immune System Disorders.

<a id="nucala-stopping-steroids"></a>

### Can patients stop their steroids after starting Nucala?

> “Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy 
> with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and 
> performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be 
> associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed 
> by systemic corticosteroid therapy.”

Source: [NUCALA: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF#page=6)

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
